RBT-1 Reduces Blood Product Use in Heart Surgery
Author Information
Author(s): Mack Charles A., Jessen Michael, Lamy Andre, Khanna Ashish K., Lobdell Kevin, Arora Rakesh, Rodriguez Jeannette, Ruiz Stacey, Singh Bhupinder
Primary Institution: Weill Cornell Medicine
Hypothesis
Does RBT-1 reduce the need for blood products in patients undergoing coronary artery bypass grafting and/or valve surgery?
Conclusion
RBT-1 treatment significantly reduced the need for blood transfusions and blood products in patients undergoing heart surgery.
Supporting Evidence
- RBT-1 reduced blood product utilization from 43.9% in the placebo group to 23.8% in the RBT-1 group.
- Patients treated with RBT-1 spent less time on the ventilator and in the ICU compared to those receiving placebo.
- The study included 152 patients across the United States, Canada, and Australia.
Takeaway
RBT-1 is a medicine that helps patients who have heart surgery use less blood, which is good for their recovery.
Methodology
This was a Phase 2, multicenter, randomized, double-blind, placebo-controlled trial with patients receiving either RBT-1 or placebo before surgery.
Potential Biases
Differences in institutional practices and individual discretion may have affected blood product usage rates.
Limitations
The study lacked a predefined protocol for blood product usage, which may have influenced the results.
Participant Demographics
Patients aged 18 years or older scheduled for nonemergency CABG and/or valve surgery.
Statistical Information
P-Value
0.0362
Statistical Significance
p=0.0362
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website